Clinical Trial Update: Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating LY450139 dihydrate (semagacestat) in individuals with mild to moderate Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LY450139 dihydrate (semagacestat) (semagacestat)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED